Kinetic constants and sample-to-sample variation in the rate of metabolism of two or more substrates for human liver microsomal CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP3A4

被引：0
|
作者：
Woodworth, Zell [1 ]
Dwyer, L. Anne [1 ]
Collins, Lisa [1 ]
Graves, Terry [1 ]
Helmstetter, Stephanie [1 ]
Ogilvie, Brian [1 ]
Otwell, Clayton [1 ]
Pope, Chad [1 ]
Ramsey, Tiffin [1 ]
Yerino, Phyllis [1 ]
Parkinson, Andrew [1 ]
机构：
[1] XenoTech LLC, Lenexa, KS USA
来源：
DRUG METABOLISM REVIEWS | 2006年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
107
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [31] Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis
    Fu, Meng
    Luo, Lin
    Feng, Sheng
    Lin, Hongda
    Lu, Zekun
    Gu, Fei
    Fan, Yang
    Wu, Bing
    Huang, Jianying
    Shen, Kai
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (12) : 3659 - 3668
  • [32] In situ evaluation of CYP1A2, CYP2B6 and CYP3A4/5 induction in human hepatocytes with a cocktail of probe substrates
    Amunom, Immaculate
    Brawner, Sarah
    Simpson, Jennifer
    Sawi, Janet
    Campbell, Rebecca
    Neat, Jason
    Parkinson, Andrew
    DRUG METABOLISM REVIEWS, 2009, 41 : 89 - 89
  • [33] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153
  • [34] Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
    Fernando de Andrés
    Catalina Altamirano-Tinoco
    Ronald Ramírez-Roa
    Carlos F Montes-Mondragón
    Pedro Dorado
    Eva M. Peñas-Lledó
    Adrián LLerena
    The Pharmacogenomics Journal, 2021, 21 : 140 - 151
  • [35] Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer
    Turner, P. Kellie
    Hall, Stephen D.
    Chapman, Sonya C.
    Rehmel, Jessica L.
    Royalty, Jane E.
    Guo, Yingying
    Kulanthaivel, Palaniappan
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (09) : 796 - 803
  • [36] ABEMACICLIB LACKS A CLINICALLY-MEANINGFUL EFFECT ON CYP1A2, CYP2C9, CYP2D6, AND CYP3A4 SUBSTRATES IN PATIENTS WITH CANCER.
    Turner, P. K.
    Hall, S. D.
    Kulanthaivel, P.
    Tate, S. C.
    Rehmel, J.
    Royalty, J.
    Guo-Avrutin, Y.
    Chiang, A. Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S34 - S34
  • [37] Kinetic analysis of fluvastatin metabolism by CYP2C9 and its allelic variants, CYP2C9*2 and CYP2C9*3
    Einolf, HJ
    Fischer, V
    DRUG METABOLISM REVIEWS, 2003, 35 : 191 - 191
  • [38] Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro:: Potential for interactions with CYP2C8 inhibitors
    Jaakkola, Tiina
    Laitila, Jouko
    Neuvonen, Pertti J.
    Backman, Janne T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 (01) : 44 - 51
  • [39] CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
    Johansson, Maria
    Strahm, Emmanuel
    Rane, Anders
    Ekstrom, Lena
    FRONTIERS IN GENETICS, 2014, 5
  • [40] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Kajosaari, LI
    Jaakkola, T
    Neuvonen, PJ
    Backman, JT
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) : 217 - 223
12345